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ABSTRACT 
BACKGROUND:  
The incidence of postoperative nausea and vomiting (PONV) after middle ear 
surgery is high. In this study we want to compare the effects of intravenous Granisetron and 
oral gabapentin as a premedication before surgery in patients undergoing middle ear 
surgeries. 
MATERIALS AND METHODS:  
We enrolled 60 patients that were randomly divided into the two groups of 30 in 
each. Group I received Granisetron 3 mg iv 2 minutes before induction of anesthesia; Group 
II received oral Gabapentin 300 mg 1 hour before induction. The incidence and severity of 
PONV were recorded each 30 minutes for 1st 6 hours in the post-anesthesia care unit 
(PACU) and each 2nd hourly 10 hours and 4th hourly for next 8 hours. The severity of nausea 
was assessed by visual analogue scale (VAS). 
RESULT:  
The incidence and severity of nausea and vomiting at different time intervals in 
Groups I and Group II was not significant. There was no significant difference in the 
incidence of side effects like respiratory depression, apnea, extra pyramidal disorders, 
drowsiness, dizziness, vertigo and headache in two groups.  
CONCLUSION:  
The study was shown that using Gabapentin and Granisetron have equal anti-emetic effects, 
These submit the efficiency of these drugs in preventing Post operative nausea and vomiting 
(PONV). 
Key Words:  
5HT3 receptors, Gabapentin, Granisetron, post operating nausea and vomiting (PONV), 
visual analogues scale 
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INTRODUCTION 
One of the commonly encountered problem in the postoperative 
recovery room is Post Operative Nausea and Vomiting. Among various 
surgeries middle ear surgery is notorious for Post Operative Nausea and 
Vomiting. Various strategies have been proposed to overcome this problem. It 
is more common following general anaesthesia occurring in 30 to 40% of all 
patients27.Post Operative Nausea and Vomiting is considered as the most 
troublesome side effect following surgery which can occur 24hrs after surgery. 
It can be prevented to some extent by changing anaesthetic technique and 
relieving patient anxiety preoperatively. 
Routine antiemetic prophylaxis is not recommended for the patients 
undergoing general anaesthesia. It is reserved only for surgeries that have high 
risk for Post Operative Nausea and Vomiting. Various class of drugs are used 
to prevent Post Operative Nausea and Vomiting like anti-dopaminergic, anti-
cholinergic, butyrophenones, phenothiazines are being used. The clinically 
significant side effects like dry mouth, extra pyramidal symptoms, sedation is 
the common disadvantage of this drugs. In this study we are going to compare 
the antiemetic effect of Granisetron and Gabapentin. 
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AIM 
The aim of this clinical trial is to compare the efficacy of prophylactic 
intravenous administration of Granisetron 3mg versus Gabapentin 300mg 
orally in preventing Post Operative Nausea and Vomiting in patients 
undergoing middle ear surgeries in adults undergoing general anaesthesia. 
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PHYSIOLOGY OF NAUSEA AND VOMITING 
NAUSEA: 
Nausea is conscious recognition of subconscious excitation in an area of 
medulla closely related to vomiting centre15. It can also be caused by 
1. Irritative impulse from GI tract 
2. Impulses from cerebral cortex to initiate vomiting. 
VOMITING: 
Vomiting is an act by which upper GI tract rids itself of its contents 
when any part of upper tract becomes excessively irritated or overdistented15. 
RETCHING: 
It is defined as laboured rhythmic activity of the respiratory musculature 
that usually precedes or accompanies vomiting. 
PHASES OF VOMITING: 
There are two primary phases involved in emesis: 
1. The prodromal phase, 
2. The vomiting phase. 
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PRODROMAL PHASE: 
1. It may be accompanied by nausea, 
2. Stimulation of sympathetic system leads to tachycardia, pupillary 
dilatation and cutaneous vasoconstriction2. 
3. Stimulation of parasympathetic system leads to salivation and 
gastro-intestinal motor activity. 
VOMITING PHASE: 
The first effects after stimulating vomiting centre are  
1. a deep breath, 
2. raising of hyoid bone and larynx to pull upper oesophageal 
sphincter open16, 
3. closing of glottis to prevent vomitus enter into lungs, 
4. lifting of soft palate to close posterior nares and afterwards there 
is a strong downward contraction of diaphragm along with 
simultaneous contraction of all abdominal muscles. This squeezes 
stomach between diaphragm and abdominal muscles building up 
intragastric pressure to a high level. Finally lower oesophageal 
sphincter relaxes completely causing expulsion of gastric 
contents upward through oesophagus16. 
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VOMITING CENTRE: 
It is located in the medulla oblongata in close proximity to the 
respiratory centre, salivation nuclei, vestibular nuclei, vasomotor nuclei. It 
receives stimulus from chemoreceptor trigger zone, nucleus Tractus solitarius, 
afferents from the abdomen , vestibular system and from certain higher centres. 
CHEMORECEPTOR TRIGGER ZONE: 
It lies within the Area Postrema(AP) of the brain stem which is a 
“U”shaped circumventricular organ located bilaterally on the floor of the fourth 
ventricle. The blood brain barrier in this region is poorly developed15. 
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ABDOMINAL VISCERAL AFFERENTS: 
The vagus nerve which is present carries the afferent signals from the 
abdomen which triggers the emetic response. The afferent impulses carried by 
the vagus nerve stimulates the emetic centre through the nucleus Tractus 
solitarius(NTS). 
The enterochromaffin cells which is present in the gut release serotonin 
in response to the irritants which activates vagal afferents. The vagal afferents 
are of two types: 
1. Chemoreceptors which is present in the mucosa of the upper gut 
and the local irritants stimulates it. 
2. Mechanoreceptors :  It is present in the wall of the gut which is 
activated by contraction and distension of the gut2 
HIGHER CENTRES: 
Emesis can also be induced by unpleasant smell, pain, taste and sight. 
VESTIBULAR SYSTEM: 
Activation of receptors due to motion sickness which stimulates 
labyrinth of inner ear signals vestibular nuclei in the cerebellum which 
stimulates chemoreceptor trigger zone triggers the vomiting centre that leads to 
emesis15. 
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MOTOR COMPONENTS OF VOMITING REFLEX : 
The motor components are mediated through somatic and autonomic 
nerves. Sensory impulses from pharynx , oesophagus, stomach are carried to 
the vomiting centre16. 
 
Sensory signals from pharynx, oesophagus, upper part of small intestine 
 
Vagal and sympathetic afferent nerve fibres 
 
Vomiting centre( multiple nuclei in the brainstem) 
 
5th,7th,9th,10th,12th cranial nerves 
 
Through vagal and sympathetic nerves to lower tract and through spinal 
nerves to diaphragm and abdominal muscles. 
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EMETIC PATHWAYS AND CENTRES RESPONSIBLE FOR EMESIS 
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CONSEQUENCES OF POST OPERATIVE NAUSEA AND 
VOMITING 
Patient : 
Postoperative pain and discomfort : The fluid and food intake is delayed  
Physiological: 
Sweating , increased in heart rate, salivation , abnormal cardiac rhythms 
and pallor. 
Medical: 
Electolyte imbalance like hypokalemia , metabolic alkalosis due to 
hyponaterimia , dehytration , orthostatic hypotension and interuption of diet. 
Surgical: 
Wound dehiscence and bleeding, oesophageal tears, increased 
intracranial and intraocular pressure, anastamotic grafts disruption, 
Anaesthesia: 
Aspiration pneumonia can occur. 
Hospital stay / cost: 
Unexpected hospital admission and delay in discharge. 
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FACTORS ASSOCIATED WITH POSTOPERATIVE 
NAUSEA AND VOMITING 
PATIENT FACTORS: 
Gender : 
Adult females are having three times increased incidence and severity of 
postoperative nausea and vomiting than adult males. 
Age : 
In infantile age group the incidence of Post Operative Nausea and 
Vomiting is less compared with late childhood where it is 34-51% and it 
remains constant throughout adult age group upto eigth decade26 . 
Smokers : 
One might predict that smokers have higher risk of Post Operative 
Nausea and Vomiting than nonsmokers , Cohen and associates found that 
nonsmokers were 1.8 times more likely than smokers to have Post Operative 
Nausea and Vomiting26. 
History of Post Operative Nausea and Vomiting or motion sickness: 
The patients with history of motion sickness or post operative nausea 
and vomiting in previous anaesthesia are more likely to develop Post Operative 
Nausea and Vomiting26. 
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Anxiety : 
Infants and children are more anxious because of that they swallow 
large volume of air and anaesthetic gases during induction which results in 
gastric distension and are prone to develop vomiting, anxiety also delays 
gastric emptying. 
Body habitus: 
Obese patients are more likely to develop Post Operative Nausea and 
Vomiting than asthenic patients. 
Menstruation : 
Studies have reported that women are more susceptible to Post 
Operative Nausea and Vomiting during first seven days of menstrual cycle7. 
SURGICAL FACTORS: 
Middle ear surgery: 
Due to increased middle ear pressure secondary to nitrous oxide , the 
incidence of Post Operative Nausea and Vomiting increases and the mechanism 
is the activation of vestibular system afferent pathway especially if the system 
is sensitized by opiods. Another pathway is the nerve supplying the tympanum 
(ie) the auricular branch of vagus nerve- Arnold`s Nerve ,its activation leads to 
emesis. 
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Adenotonsillectomy : 
The irritation of trigeminal nerve during surgery and the irritant effect of 
swallowed blood on the oesophago-gastric chemoreceptors results in higher 
incidence of Post Operative Nausea and Vomiting. 
Abdominal surgery: 
The direct effect of vagal afferents and the release of 5HT  from the 
enterochromaffin cells due to surgical manipulation of intestine stimulates 
vomiting centre which results in emesis. 
Post Operative Nausea and Vomiting incidence over 24 hours was 42% 
for “emetogenic procedures” compared with other surgical procedures( 36%)26. 
Gynaecological surgery 
Laproscopic surgeries like abdominal hysterectomy is associated with 
increased incidence of Post Operative Nausea and Vomiting ( upto 65 -77%). 
Opthalmic surgery  
Strabismus surgery is the common surgery associated with high 
incidence of Post Operative Nausea and Vomiting 
Duration of anaesthesia 
Increase in the duration of the surgery is associated with higher 
incidence and severity of postoperative nausea and vomitting. 
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ANAESTHETIC FACTORS 
Premedication  
Anticholinergics like Glycopyrolate cause more Post Operative Nausea 
and Vomiting than Atropine. Hence in patients with predisposing factors for 
Post Operartive Nausea and Vomiting, Atropine is preferred over 
Glycopyrolate. 
Opioids  
All opioids in general cause emesis of which Morphine and Pethidine 
cause maximum emesis. It is mediated through µ-receptors in Area postrema. It 
also increase the sensitivity of emetic reflex by labrythine stimulation. 
Morphine and other opioids enhance the release of 5HT from small intestine. 
Benzodiazepines  
In general it does not causePost Operartive Nausea and Vomiting though 
temazepam has found to increase the risk of Post Operartive Nausea and 
Vomiting. 
I V Induction agents 
Out of various induction agents available Propofol is associated with 
least incidence of Post Operative Nausea and Vomiting. Thiopentone sodium is 
better than etomidate in reducing the incidence of Post Operartive Nausea and 
Vomiting26. 
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Intubation  
During insertion of airway pharangeal mechanoreceptors are stimulated 
via glossophrangeal nerve and these project into the brainstem. 
Inhalational anaesthetic agents 
Nitrous oxide (N2O) 
Nitrous oxide by its action on central opioid receptors , gut distension 
and increased pressure in the middle ear increase the incidence of Post 
Operative Nausea and Vomiting. 
Volatile anaesthetic agent 
Modern volatile agents like Isoflurane , Sevoflurane , Desflurane has the 
less incidence of Post Operartive Nausea and Vomiting than older agents. 
Neuromuscular blocking drugs  
In general these drugs does not have effects on Post Operartive Nausea 
and Vomiting but reversal drug Neostigmine has been implicated with 
increased incidence of Post Operartive Nausea and Vomiting. 
Anaesthetic techinque 
Regional anaesthesia is associated with less incidence of Post Operartive 
Nausea and Vomiting than general anaesthesia. 
Movements  
Post Operative Nausea and Vomiting can occur when there is a sudden 
jerky movements while shifting the patients.  
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ROLE OF 5HT IN POST OPERATIVE NAUSEA  
AND VOMITING 
Both peripheral and central mechanisms are involved in the control of 
emesis. The 5HT and 5HT3 receptors are involved in eliciting the mechanism 
for emesis which has been proven in the animal model9. 
The discovery of 5HT3 receptor antagonists in control of chemotherapy 
and radiotherapy induced emesis has led to the clinical evaluation of 
Granisetron in preventing postoperative nausea and vomiting9. 
In the CNS the 5HT3 receptors are more abudant in the NTS-AP 
regions. The chemoreceptor trigger zone is located in this region. 
Most vagal afferents from the periphery enter the brain from GIT where 
the concentration of 5HT3 receptors are higher.  
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PERIPHERAL PATHWAYS: 
Surgical procedures, anaesthetic agents 
(gut manipulation , laparotomy ) 
 
Damage to GI tract and irritation of gut mucosa Head and neck surgery 
 
Release of paracrine neurotransmitter like 5HT 
Activates5HT3 
receptor in V 
Cranial nerve 
 Firing of vagal afferents 
 
Terminate in area postrema and NTS regions 
 Sensory afferents of V CN 
 Terminates in NTS Region 
INITIATION OF VOMITING REFLEX 
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RECENT TRENDS IN THE MANAGEMENT OF POST 
OPERATIVE NAUSEA AND VOMITING 
Post Operative Nausea and Vomiting is the result of interaction of many 
factors like type of surgery, age, gender , use of opioids , anaesthetic agents etc. 
It is apparent that single antiemetic drug will not be effective in all conditions. 
Many pharmacological and non-pharmacological therapies has been 
evaluated in the treatment of Post Operative Nausea and Vomiting. 
PHARMACOLOGICAL PROPHYLAXIS 
1. Butyrophenones ( eg . Droperidol ) is a dopamine receptor 
blocker which is present in CTZ. Use of droperidol is associated 
with the side effect of QT prolongation and torsades de pointes 
syndrome. 
2. Metaclopramide is an another dopamine receptor blocker present 
in CTZ. It acts by shortening the bowel transit time and blocks 
seratonin receptors at high doses. The disadvantage of the drug is 
extrapyramidal symptom as side effect. 
3. Dimenhydrinate an antihistaminic is also used as an antiemetic. 
4. Scopolamine an anticholinergic can block muscarinic recaptors 
responsible for emesis. 
5. Recently , Diclectin26 is found to be effective as Ondansetron. It 
contains doxylamine succinate, with 10mg Pyridoxine 
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hydrochloride. Pyridoxine may have intrinsic antiemetic property 
and may also be synergestic with antihistamines. 
6. Aprepitant a NK -1 receptor26 antagonist has been approved for 
treatment of Post Operative Nausea and Vomiting. It blocks NK-
1 receptors in the CNS and PNS results in prevention of emesis. 
7. The futured therapies in prevention of Post Operartive Nausea 
and Vomiting are the use of cannabinoids and peripheral opioid 
antagonist – Naloxone. 
The baseline risk factors which can be reduced are as follows 
1. Use of regional anaesthesia 
2. Use of propofol for induction and maintenance of anaesthesia 
3. Avoidance of Nitrous oxide (N2O ) 
4. Avoidance of volatile agents 
5. Reduction of intraop and postop opioids 
NON – PHARMACOLOGIC THERAPY 
In selected group of patients , Acupunture has been found to be effetive 
in preventing Post Operative Nausea and Vomiting10. 
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PHARMACOLOGY OF GRANISETRON 
INTRODUCTION 
Granisetron is a selective 5HT3 receptor antagonist which is synthesized 
in 1988 and the drug was approved by FDA in 199421. 
CHEMISTRY 
Formula C18H24N4O 
Molecular weight: 312.4g/mol 
MOLECULAR STRUCTURE OF GRANISETRON HYDROCHLORIDE 
 
 
PHARMACOLOGY 
It is a 5HT3 receptor antagonist with a main action at the vomiting 
centre at medulla. It mainly reduces the activity of vagus nerve hence used for 
chemotherapy induced nausea and vomiting. 
Actions 
There is no demonstrable effect on heart rate, cardiac output, blood 
pressure and electrocardiogram. 
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Pharmacokinetics 
It may be given orally,intravenously and transdermal patch.  
Absorption :  Oral absorption in an empty stomach is 30%. Mean 
plasma half-life is 7 to 9 hours. 
Distribution : Granisetron freely distributes between plasma and red 
blood cells. It is 65% bound to plasma proteins. 
Metabolism : It is metabolized in the liver . The major route 
involves N-demethylation and aromatic ring oxidation followed by 
conjugation. Metabolism is modulated by cytochrome P450 3A. 
Elimination : Predominantly by hepatic metabolism, 11% of the 
drug eliminated unchanged in urine and no dose change required in renal 
failure18. 
PREPARATION 
Oral:   1 mg or 2 mg of Granisetron hydrochloride. 
Parenteral : Isotonic aqueous solution of Granisetron 
hydrochloride 3mg/3ml vial. 
THERAPEUTIC USES 
1. It is used in control of nausea and vomiting due to chemotherapy induced 
emesis.  
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2. Used for both acute and chronic illness of postoperative nausea and 
vomiting. 
3. Used to treat acute gastroenteritis induced vomiting 
CONTRAINDICATIONS 
Hypersensitivity to any of the components. 
ADVERSE EFFECTS 
Granisetron is generally well tolerated. Headache, dizziness are the side 
effects. Constipation is the commonest complaint18.  
WARNING: Serotonin syndrome development has been noticed with 
5HT3 antagonist. 
DOSE: Optimum dose for intravenous administration is 3mg in adults. 
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PHARMACOLOGY OF GABAPENTIN 
INTRODUCTION 
Gabapentin is an amino acid analogue of GABA, the neurotransmitter. It 
was originally used as spasmodic but recently more used for partial seizures 
and for analgesia. It was approved by FDA in 1993. 
CHEMISTRY 
Formula:   C9H17NO2 
Molecular weight: 171.2 g/mol 
 
MOLECULAR STRUCTURE OF GABAPENTIN 
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PHARMACOLOGY 
Mechanism of action 
Though it is similar in similarity to GABA, it do not act directly on 
GABA receptor. It modifies the synaptic or postsynaptic release of GABA. It 
binds avidly to α2δ subunit of voltage gated calcium channels. It also acts 
presynaptically and decreases glutamate release21. 
The mechanism by which it reduces the Post Operative Nausea and 
Vomiting is unclear, the postulated mechanism is, it reduces the activity of 
tachykinin neurotransmitter, decrease the calcium influx in Area postrema, by 
opioid sparing effect, by reducing the inflammation at the surgical site5. 
Pharmacokinetics 
Absorption : The drug is absorbed orally and is non linear and dose 
dependent at very high doses. The bioavailability of the drug is 27-60%. 
Distribution : The drug is not bound to plasma proteins , hence the drug 
interaction is negligible21. 
Metabolism : It is not metabolized and does not induce liver enzymes. 
Elimination : It is eliminated by the kidneys and it is linear. It is excreted 
unchanged in urine. 
Half life of the drug is 5 to 8 hours. 
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Preparation : it is available as  
Capsule- 100mg, 300mg and 400 mg 
Tablet – 300mg, 600mg and 800mg 
Oral solution – 250mg /5ml. 
USES 
It is used in the treatment of 
1. Partial seizures 
2. Post herpetic neuralgia 
3. Restless leg syndrome 
4. Cocaine withdrawal 
5. Insomnia 
6. Diabetic neuropathy  
7. Tremors in multiple sclerosis  
8. Cancer related hot flushes 
9. Amyotrophic lateral sclerosis 
Adverse effects: drowsiness, dizziness and fatigue21. 
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REVIEW OF LITERATURE 
1. Fuji et al 2003;25: 1142-9 published a randomized double blind study 
in British Journal of Anaesthesia regarding the efficacy and safety of 
Granisetron , Droperidol and combination of both in preventing Post 
Operative Nausea and Vomiting for patients undergoing breast 
surgery. They found the incidence of Post Operative Nausea and 
Vomiting during first 24hours of postoperative period as 18% with 
Granisetron , 38% with Droperidol and 4% with a combination of 
Granisetron and Droperidol when given immediately before induction 
of anaesthesia and a standard anaesthetic technique was used13 
2. Pandey CK et al 2006;52:97-100 conducted a randomized , double 
blind placebo controlled study to evaluate the effect of Gabapentin 
600mg orally 2 hours before surgery in prevention of Post Operative 
Nausea and Vomiting in patients undergoing laparoscopic 
cholecystectomy. A total of 250 patients were randomly assigned into 
placebo and Gabapentin group. They concluded that Gabapentin 
effectively suppressed Post Operative Nausea and Vomiting and 
rescue analgesic requirement postoperatively32. 
  
 26 
 
3. Khademi S et al 2010;19:57-60 conducted a preoperative randomized 
double blind placebo controlled study to evaluate the effect of 
Gabapentin 600mg orally on severity of Post Operative Nausea and 
Vomiting in patients undergoing open cholecystectomy. A total of 90 
patients were randomly assigned into placebo and Gabapentin group. 
They concluded that patients in Gabapentin group had significant 
decreased Post Operative Nausea and Vomiting and analgesic 
requirement in the postoperative period23. 
4. Ajori et al 2012;285:677-82 conducted a double blinded randomized 
clinical trial to evaluate the effect of pre-emptive use of Gabapentin 
600 mg orally on postoperative pain and Post Operative Nausea and 
Vomiting, rescue analgesia use and antiemetic drug requirement in 
patients undergoing abdominal hysterectomy. A total of 140 patients 
were randomly assigned into placebo and Gabapentin group. They 
concluded that patients in Gabapentin group had significant decreased 
Post Operative Nausea and Vomiting and antiemetic requirement in 
the postoperative period3. 
5. AshutoshSayana et al 2012;2:2231-4423 their comparative study of 
Metoclopramide, Ondansetron and Granisetron in prophylaxis of Post 
Operative Nausea and Vomiting in patients undergoing laparoscopic 
cholecystectomy under general anaesthesia. According to them there 
was no statistically significant difference was found among three 
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groups in 0 – 2 hours and beyond 12 hours postoperative period , but 
2-12 hour postoperative period showed a statistically significant , 
more effective prevention of Post Operative Nausea and Vomiting in 
Granisetron group6. 
6. Firdose et al 2012;32 conducted a prospective , randomized double 
blind study in evaluating the efficacy of Granisetron with or without 
Dexamethasone for elective head and plastic surgery showed a 
statistically significant difference in the occurrence of postoperative 
nausea and vomiting. Although the addition of Dexamethasone further 
decreased the incidence of nausea and vomiting upto 24 hours but 
statistically significant difference was found11. 
7. Mohammed MH et al 2014;30:225-8 conducted a randomized double 
blind, placebo controlled study to evaluate the effect of pre-emptive 
use of Gabapentin 20mg / kg on severity of POV in paediatric patients 
(4-8 years) undergoing adenotonsillectomy. A total of 144 patients 
were randomly assigned to Gabapentin and placebo group. They 
concluded that Gabapentin effectively reduced POV and analgesic 
requirement postoperatively29. 
8. Nethra et al 2014;4:2249-6467 in international journal of 
pharmacology and therapeutics had published a research article stating 
the results of Granisetron with Dexamethasone and Ondansetron with 
Dexamethasone and placebo in reducing Post Operative Nausea and 
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Vomiting for patients undergoing gynaecological procedures. 
According to them, the incidence of Post Operative Nausea and 
Vomiting for females undergoing gynaecological procedure is 72% . 
A comparative study of the above three groups showed that the 
incidence of Post Operative Nausea and Vomiting was 60% , 12% and 
12% for placebo , Granisetron , Ondansetron groups respectively. The 
granisetron100mg + Dexamethasone 8mg , Ondansetron 4 mg + 
dexamethasone 8 mg showed no statistical difference in preventing 
Post Operative Nausea and Vomiting when administered 
prophylactically , placebo group showed higher incidence of Post 
Operative Nausea and Vomiting30. 
9. S.Achuthan et al 2015;114:588-97 conducted a quantitative analysis 
of evidence from seventeen randomized placebo controlled trials 
involving administration of Gabapentin preoperatively in patients 
undergoing elective abdominal procedures. Their analysis assessed 
nausea, vomiting and rescue antiemeticuse in postoperative period and 
conducted from their analysis that the relative risk for nausea as 
0.76,0.62 for vomiting, o.71 for composite Post Operative Nausea and 
Vomiting and 0.6 for rescue antiemetic use. They had concluded that 
preoperative Gabapentin helps in preventing Post Operative Nausea 
and Vomiting in patients undergoing abdominal surgeries5. 
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10. MortezaHeidari et al 2015;4:22 studied the effect of Granisetron and 
Gabapentin in preventing Post Operative Nausea and Vomiting in 
patients undergoing middle ear surgeries in adults under general 
anaesthesia in three groups with control as the third group , the study 
was conducted in 90 patients. They concluded that the both drugs 
have equal antiemetic effect in preventing Post Operative Nausea and 
Vomiting compared with control group28. 
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SAMPLE SIZE CALCULATION 
Sample size was determined based on  
Study  
Granisetron versus gabapentin in preventing postoperative nausea and 
vomiting after middle ear surgery in adults: A double blinded randomized 
clinical trial study 
Authored by  
Morteza Heidari et al 
Published in 
Adv Biomed Res 2015;4:22. 
In this study the ASA classification between the two groups had a 
difference of 19%.  
Description: 
 The confidence level is estimated at 95% 
 with a z value of 1.96 
 the confidence interval or margin of error is estimated at +/-10 
 Assuming that 80 percent of the sample will have the specified 
attribute p% =19 and q%=81 
n = p% x q% x [z/e%] ² 
n= 19 x 81 x [1.96/10]² 
n= 59 
Therefore 59 is the minimum sample size required for the study. 
In our study 60 subjects were chosen (n=30 in Gabapentin arm and n=30 
in Granisetron arm)  
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MATERIALS AND METHODS 
This was a randomised, double blinded study conducted at the Institute 
of Anaesthesiology and Critical Care, Madras Medical College, Chennai. Sixty 
patients between ages of 18 to 60 yrs, who were scheduled to undergo elective 
middle ear surgeries under general Anaesthesia were included in the study. 
Informed consent regarding the procedure was obtained from all 
patients. Pre-operatively the patients were educated about the visual analogue 
scale. They were shown the scale and were taught how to rate the severity of 
nausea post-operatively. The scale was graded from 0 to 10cm. “0” indicated 
no nausea at all and “10” was very severe nausea. The scale was divided into 3 
equal portions to denote mild, moderate and severe nausea respectively. 
The inclusion criteria included the following: 
 ASA-1,2 
 Age group 18-60 years. 
 Undergoing any middle ear surgery. 
The exclusion criteria were as follows: 
 Pregnant females 
 History of addiction or using antiemetics 
 BMI>30 
 Any cerebellar problems 
 Uncontrolled bleeding during surgery  
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 History of Post Operative Nausea and Vomiting after previous 
surgery 
 History of motion sickness 
 Duration of surgery > 2 hrs 
The patient were premedicated with 0.01mg/kg of Glycopyrolate and 
2µg/kg of Fentanyl after connecting the monitors and securing intravenous line.  
 The patients were randomly allocated to two groups. Group A and  
Group B. 
Group A received 3mg iv in a volume of 3 ml 2 minutes prior to 
induction and group B received 3mg Gabapentin 1 hour before induction. After 
5 minutes of preoxygenation anaesthesia was induced with 5mg/kg of 2.5%  
iv Thiopentone sodium , intubation was facilitated by giving 0.5mg/kg of 
Atracurium and ventilated for 5 minutes and then trachea was intubated with 
cuffed endotracheal tube of appropriate size. Anaesthesia was maintained with 
intermittent positive pressure ventilation with 60:40 nitrous oxide and oxygen, 
0.8 to 1.2% Isoflurane and Atracurium was used for muscle relaxation. 
Increment doses of fentanyl were given as necessary. 
INTRA-OPERATIVE MONITORING 
During intraoperatively the heart rate, ,non-invasive blood pressure, 
oxygen saturation monitoring were done. Intraoperative fluid balance was 
maintained with 10ml/kg/hr of normal saline. Blood loss was assessed using 
weighing method and blood was replaced if the loss is >10% of patients blood 
volume.  
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Blood pressure, heart rate , oxygen saturation were recorded every 5 
minutes during the procedure. At the end of surgery inj.Neostigmine 
0.05mg/kg and inj.Glycopyrolate 0.01mg/kg given intravenously to reverse the 
neuromuscular blockade. The duration of surgery was noted. The patient was 
shifted to post anaesthetic care unit (PACU) after recovery.  
Heart rate, blood pressure and oxygen saturation(SpO2) were monitored 
for every half an hour for the first 6hrs and then every 2 hrs. Nausea and 
vomiting were assessed soon after recovery and in the PACU for every ½ hour. 
for first 6 hour and then 2nd hourly for next 10hoursand then 4th hourly for next 
8 hrs. Nausea is the subjective sensation which is assessed by using visual 
analogue scale (VAS) The patients were taught already about how to rate their 
nausea in the visual analogue scale and according to that nausea was classified 
as mild, moderate and severe. 
Severity of vomiting was classified as follows: 
 Mild:1 - 2 episodes; 
 Moderate: 3-4 episodes; 
 Severe:more than 4 episodes. 
In case of severe vomiting inj. Metoclopramide 10 mg iv was given as a 
rescue antiemetic. Patients were also asked for any other complaints like 
headache, dizziness and appropriate treatment was given.  
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DATA ANALYSIS 
Descriptive statistics was done for all data and were reported in terms of 
mean values and percentages. Suitable statistical tests of comparison were 
done. Continuous variables were analysed with the unpaired t test.. Categorical 
variables were analysed with the Chi-Square Test and Fisher Exact Test. 
Statistical significance was taken as P < 0.05. The data was analysed using 
SPSS version 16 and Microsoft Excel 2007. 
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Age Distribution 
 
 
 
Age Distribution Gabapentin % Granisetron % 
≤ 30 years 9 30.00 8 26.67 
31-40 years 13 43.33 12 40.00 
41-50 years 8 26.67 10 33.33 
Total 30 100 30 100 
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Age Distribution Gabapentin Granisetron 
N 30 30 
Mean 34.87 34.83 
SD 8.44 8.56 
P value Unpaired t Test 0.9879 
 
 
Majority of the Gabapentin group patients belonged to the 31-30 years 
age class interval (n=13, 43.33%) with a mean age of 34.87 years. In the 
Granisetron group patients, majority belonged to the same age class interval 
(n=12, 40%) with a mean age of 34.83 years. The association between the 
intervention groups and age distribution is considered to be not statistically 
significant since p > 0.05 as per unpaired t test.  
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Gender Distribution 
 
 
Gender Distribution Gabapentin % Granisetron % 
Male 16 53.33 15 50.00 
Female 14 46.67 15 50.00 
Total 30 100 30 100 
P value Chi Squared Test 0.9999 
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Majority of the Gabapentin group patients belonged to the male gender 
class interval (n=16, 53.33%). In the Granisetron group patients, majority 
belonged to the same gender class interval (n=15, 50%). The association 
between the intervention groups and gender distribution is considered to be not 
statistically significant since p > 0.05 as per chi squared test 
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BMI Distribution 
 
 
BMI Distribution Gabapentin % Granisetron % 
Underweight (≤ 18.49) 0 0.00 0 0.00 
Normal (18.50 to 24.99) 15 50.00 17 56.67 
Overweight (25 to 29.99) 15 50.00 13 43.33 
Obese 0 0.00 0 0.00 
Total 30 100 30 100 
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BMI Distribution Gabapentin Granisetron 
N 30 30 
Mean 24.17 24.10 
SD 1.49 1.83 
P value Unpaired t Test 0.8774 
 
Majority of the Gabapentin group patients belonged to the normal BMI 
class interval (n=15, 50%) with a mean BMI of 24.17. In the Granisetron group 
patients, majority belonged to the same BMI class interval (n=17, 56.67%) 
with a mean BMI of 24.10. The association between the intervention groups 
and BMI distribution is considered to be not statistically significant since p > 
0.05 as per unpaired t test.  
 41 
 
ASA Physical Classification 
 
 
ASA Physical Classification Gabapentin % Granisetron % 
ASA 1 13 43.33 16 53.33 
ASA 2 17 56.67 14 46.67 
Total 30 100 30 100 
P value Chi Squared Test 0.8812 
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Majority of the Gabapentin group patients belonged to the ASA 2 class 
interval (n=17, 56.67%). In the Granisetron group patients, majority belonged 
to the ASA 1 class interval (n=16, 53.33%). The association between the 
intervention groups and ASA Physical Classification is considered to be not 
statistically significant since p > 0.05 as per chi squared test 
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Heart Rate 
 
 
Heart 
Rate BI AI 5 mins 
10 
mins 
15 
mins 
30 
mins 
45 
mins 
60 
mins 
90 
mins 
G
ab
ap
en
tin
 
N 30 30 30 30 30 30 30 30 27 
Mean 100.37 107.67 91.37 87.07 85.23 83.50 84.03 82.40 82.11 
SD 13.43 12.60 14.21 13.05 14.04 15.27 15.57 15.76 14.71 
G
ra
ni
se
tr
on
 N 30 30 30 30 30 30 30 30 30 
Mean 100.07 77.80 76.87 75.03 74.30 73.57 73.30 73.83 72.40 
SD 11.81 8.66 10.01 8.50 8.07 8.62 8.85 9.89 8.60 
P values  
Unpaired t 
Test 
0.9271 0.4171 0.5057 0.3491 0.3067 0.2206 0.1412 0.1468 0.2063 
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Majority of the Gabapentin group patients belonged had a before-after 
induction and intraoperatively mean heart rate of 89.30 bpm with a mean range 
of 82-108 bpm. In the Granisetron group patients had a mean heart rate of 
77.46 bpm with a mean range of 72-100 bpm. The association between the 
intervention groups and heart rate before-after induction and intraoperatively is 
considered to be not statistically significant since p > 0.05 as per unpaired t test 
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Systolic Blood Pressure 
 
 
Systolic 
Blood 
Pressure 
BI AI 5 mins 10 mins 
15 
mins 
30 
mins 
45 
mins 
60 
mins 
90 
mins 
G
ab
ap
en
tin
 N 30 30 30 30 30 30 30 30 27 
Mean 139.10 119.00 121.70 119.47 120.90 122.13 122.37 121.83 124.22 
SD 17.03 15.83 17.89 16.47 17.65 14.74 11.87 11.23 12.97 
G
ra
ni
se
tr
on
 N 30 30 30 30 30 30 30 30 30 
Mean 142.93 114.30 115.03 112.83 112.73 116.13 117.63 116.77 117.77 
SD 10.03 8.69 7.36 9.43 9.51 8.59 8.86 8.97 9.10 
P values 
Unpaired  
t Test 
0.1361 0.1768 0.1490 0.1447 0.1486 0.0132 0.0108 0.0980 0.1754 
  
13
9
11
9
12
2
11
9
12
1
12
2
12
2
12
2
12
4
14
3
11
4
11
5
11
3
11
3 11
6
11
8
11
7
11
8
0
20
40
60
80
100
120
140
160
BI AI 5 mins 10 mins 15 mins 30 mins 45 mins 60 mins 90 mins
M
ea
n 
SB
P 
(m
m
 H
g)
Systolic Blood Pressure
Gabapentin Granisetron
 46 
 
 
Majority of the Gabapentin group patients belonged had a before-after 
induction and intraoperatively mean SBP of 123.41 mm Hg with a mean range 
of 119-139 mm hg. In the Granisetron group patients had a mean SBP of 
118.46 mm Hg with a mean range of 114-143 mm Hg. The association between 
the intervention groups and systolic blood pressure before-after induction and 
intraoperatively is considered to be not statistically significant since p > 0.05 as 
per unpaired t test  
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Diastolic Blood Pressure 
 
 
Diastolic 
Blood 
Pressure 
BI AI 5 mins 10 mins 
15 
mins 
30 
mins 
45 
mins 
60 
mins 
90 
mins 
G
ab
ap
en
tin
 N 30 30 30 30 30 30 30 30 27 
Mean 89.00 81.97 83.53 82.47 83.90 82.33 80.73 80.93 82.85 
SD 8.73 11.90 14.37 13.40 14.29 10.35 8.63 8.17 9.72 
G
ra
ni
se
tr
on
 N 30 30 30 30 30 30 30 30 30 
Mean 89.70 78.87 79.90 78.90 77.87 78.03 78.53 79.13 78.33 
SD 7.97 7.17 7.70 7.79 8.16 8.92 8.80 7.07 8.94 
P values 
Unpaired  
t Test 
0.7470 0.2276 0.2286 0.2138 0.0505 0.0901 0.3321 0.3654 0.0744 
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Majority of the Gabapentin group patients belonged had a before-after 
induction and intraoperatively mean DBP of 83.08 mm Hg with a mean range 
of 81-89 mm hg. In the Granisetron group patients had a mean SBP of 79.92 
mm Hg with a mean range of 78-90 mm Hg. The association between the 
intervention groups and diastolic blood pressure before-after induction and 
intraoperatively is considered to be not statistically significant since p > 0.05 as 
per unpaired t test  
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Mean Arterial Pressure 
 
 
Mean 
Arterial 
Pressure 
BI AI 5 mins 10 mins 
15 
mins 
30 
mins 
45 
mins 
60 
mins 
90 
mins 
G
ab
ap
en
tin
 N 30 30 30 30 30 30 30 30 28 
Mean 106.37 93.43 96.13 94.67 95.73 94.60 94.40 94.33 104.32 
SD 9.90 12.58 15.36 14.47 15.32 12.13 9.82 8.83 59.97 
G
ra
ni
se
tr
on
 N 30 30 30 30 30 30 30 30 30 
Mean 107.33 90.63 91.50 89.10 89.07 90.00 91.30 91.07 91.80 
SD 7.99 7.85 8.11 8.62 8.70 9.20 8.77 7.28 7.55 
P values 
Unpaired 
 t Test 
0.6790 0.3063 0.1511 0.0766 0.0439 0.1038 0.2023 0.1236 0.2822 
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Majority of the Gabapentin group patients belonged had a before-after 
induction and intraoperatively mean MAPof 97.11 mm Hg with a mean range 
of 93-106 mm hg. In the Granisetron group patients had a mean SBP of 92.42 
mm Hg with a mean range of 89-107 mm Hg. The association between the 
intervention groups and mean arterial pressure before-after induction and 
intraoperatively is considered to be not statistically significant since p > 0.05 as 
per unpaired t test  
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Oxygen Saturation (SPO2) 
 
 
Peripheral 
Capillary 
Oxygen 
Saturation 
BI AI 5 mins 10 mins 
15 
mins 
30 
mins 
45 
mins 
60 
mins 
90 
mins 
G
ab
ap
en
tin
 N 30 30 30 30 30 30 30 30 30 
Mean 98.90 98.93 98.77 98.97 98.90 98.90 99.00 98.83 98.87 
SD 0.31 0.25 0.43 0.18 0.31 0.31 0.00 0.38 0.35 
G
ra
ni
se
tr
on
 N 30 30 30 30 30 30 30 30 30 
Mean 98.90 98.57 98.73 98.80 98.77 98.77 98.97 98.73 98.83 
SD 0.31 0.50 0.45 0.41 0.43 0.43 0.18 0.45 0.38 
P values 
Unpaired  
t Test 
1.0000 0.1122 0.7703 0.2472 0.1720 0.1720 0.3256 0.3557 0.7232 
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Majority of the Gabapentin group patients belonged had a mean before-
after induction and intraoperatively SPO2of 98.90 % with a mean range of 98-
99 %. In the Granisetron group patients had a mean SPO2of 98.79 % with a 
mean range of 98-99 %.. The association between the intervention groups and 
peripheral capillary oxygen saturation before-after induction and 
intraoperatively is considered to be not statistically significant since p > 0.05 as 
per unpaired t test 
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Heart Rate
 
 
Heart Rate - 
Postoperative 0 hr 1 hr 1.5 hr 2 hr 2.5 hr 3 hr 3.5 hr 4 hr 4.5 hr 5 hr 
G
ab
ap
en
tin
 
N 30 30 30 30 30 30 30 30 30 30 
Mean 74.37 72.17 68.23 71.20 71.50 71.03 70.47 70.83 70.73 70.90 
SD 9.07 8.65 7.78 7.75 7.46 8.58 7.19 6.69 7.23 8.62 
G
ra
ni
se
tr
on
 N 30 30 30 30 30 30 30 30 30 30 
Mean 72.40 70.03 69.90 70.13 69.63 69.53 68.93 69.07 68.17 68.80 
SD 8.60 7.28 8.12 7.51 7.39 7.37 8.41 7.02 7.33 7.50 
P values 
Unpaired 
 t Test 
0.07 0.06 0.07 0.07 0.07 0.06 0.08 0.08 0.08 0.08 
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POST-OPERATIVE HEART RATE  
 
 
Heart Rate - 
Postoperative 5.5 hr 6 hr 8 hr 10 hr 12 hr 14 hr 16 hr 20 hr 24 hr 
G
ab
ap
en
tin
 N 30 30 30 30 30 30 30 30 30 
Mean 68.60 70.37 70.30 71.27 71.03 71.97 71.23 72.87 70.53 
SD 9.13 8.83 7.68 7.52 7.17 7.48 6.36 7.15 7.21 
G
ra
ni
se
tr
on
 N 30 30 30 30 30 30 30 30 30 
Mean 68.13 68.37 69.73 70.37 70.73 69.57 69.00 68.63 68.10 
SD 6.65 6.68 7.18 8.91 7.51 6.54 7.35 7.13 6.47 
P values 
Unpaired t Test 0.07 0.07 0.08 0.08 0.07 0.08 0.07 0.08 0.07 
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Results  
By conventional criteria the association between the intervention groups 
and heart rate postoperatively is considered to be statistically insignificant since 
p >0.05 as per unpaired test 
Conclusion  
In this study we can safely conclude that there is no significant 
difference in post operative heart rate between Gabapentin and Granisetron 
group. 
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Systolic Blood Pressure 
 
 
Systolic Blood 
Pressure - 
Postoperative 
0 hr 1 hr 1.5 hr 2 hr 2.5 hr 3 hr 3.5 hr 4 hr 4.5 hr 5 hr 
G
ab
ap
en
tin
 N 30 30 30 30 30 30 30 30 30 30 
Mean 122.13 115.03 114.07 113.40 113.83 113.43 113.57 113.57 113.07 114.13 
SD 8.04 6.57 5.78 6.44 7.02 7.21 6.52 6.73 6.14 6.96 
G
ra
ni
se
tr
on
 N 30 30 30 30 30 30 30 30 30 30 
Mean 118.30 114.57 114.20 113.73 112.63 112.90 113.97 113.23 112.47 112.53 
SD 8.61 7.04 6.41 6.21 6.71 6.91 7.39 6.82 6.96 7.24 
P values 
Unpaired  
t Test 
0.0800 0.7917 0.9328 0.8389 0.5012 0.7710 0.8249 0.8496 0.7245 0.3865 
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Systolic 
Blood 
Pressure - 
Postoperative 
5.5 hr 6 hr 8 hr 10 hr 12 hr 14 hr 16 hr 20 hr 24 hr 
G
ab
ap
en
tin
 N 30 30 30 30 30 30 30 30 30 
Mean 114.37 114.47 113.83 112.60 113.10 112.80 113.27 112.40 111.73 
SD 8.80 8.25 8.17 8.43 8.22 7.53 7.63 7.10 6.52 
G
ra
ni
se
tr
on
 N 30 30 30 30 30 30 30 30 30 
Mean 112.37 111.93 114.73 113.83 113.37 113.23 112.77 112.90 112.50 
SD 6.56 6.65 8.79 7.12 6.02 5.63 6.16 5.79 5.33 
P values 
Unpaired 
 t Test 
0.3226 0.1958 0.6827 0.5428 0.8866 0.8017 0.7812 0.7661 0.6199 
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Majority of the Gabapentin group patients belonged had a mean 
postoperative SBP of 113.94 mm Hg with a mean range of 112-115 mm hg. In 
the Granisetron group patients had a mean SBP of 113.48 mm Hg with a mean 
range of 112-118 mm Hg. The association between the intervention groups and 
postoperative systolic blood pressure is considered to be not statistically 
significant since p > 0.05 as per unpaired t test 
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Diastolic Blood Pressure 
 
 
Diastolic 
Blood 
Pressure - 
Postoperative 
0 hr 1 hr 1.5 hr 2 hr 2.5 hr 3 hr 3.5 hr 4 hr 4.5 hr 5 hr 
G
ab
ap
en
tin
 N 30 30 30 30 30 30 30 30 30 30 
Mean 81.80 76.77 75.43 75.60 75.67 75.10 74.33 74.47 74.33 75.13 
SD 8.97 7.31 7.06 6.98 7.32 7.00 6.70 6.64 6.69 7.23 
G
ra
ni
se
tr
on
 N 30 30 30 30 30 30 30 29 30 30 
Mean 78.63 76.40 75.73 76.00 76.00 76.20 75.60 76.28 76.40 76.53 
SD 8.98 7.32 7.32 7.41 7.43 7.12 7.48 7.61 7.34 7.17 
P values 
Unpaired  
t Test 
0.177 0.85 0.88 0.83 0.86 0.55 0.49 0.33 0.26 0.45 
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Diastolic Blood 
Pressure - 
Postoperative 
5.5 hr 6 hr 8 hr 10 hr 12 hr 14 hr 16 hr 20 hr 24 hr 
G
ab
ap
en
tin
 N 30 30 30 30 30 30 30 30 30 
Mean 76.67 76.87 76.20 75.57 74.93 75.50 75.07 74.57 74.23 
SD 8.00 7.80 5.98 5.61 6.25 8.03 8.03 6.74 5.68 
G
ra
ni
se
tr
on
 N 30 30 30 30 30 30 30 30 30 
Mean 77.13 76.13 78.07 76.63 76.50 76.60 75.97 76.10 76.17 
SD 7.69 7.67 9.10 7.82 7.70 7.24 8.89 8.55 8.77 
P values 
Unpaired  
t Test 
0.8186 0.7148 0.3524 0.5463 0.3907 0.5797 0.6821 0.4438 0.3159 
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Majority of the Gabapentin group patients belonged had a mean 
postoperative DBP of 75.70 mm Hg with a mean range of 74-82 mm hg. In the 
Granisetron group patients had a mean DBP of 76.48 mm Hg with a mean 
range of 76-79 mm Hg. The association between the intervention groups and 
postoperative diastolic blood pressure is considered to be not statistically 
significant since p > 0.05 as per unpaired t test 
  
 62 
 
Mean Arterial Pressure 
 
 
Mean 
Arterial 
Pressure - 
Postoperative 
0 hr 1 hr 1.5 hr 2 hr 2.5 hr 3 hr 3.5 hr 4 hr 4.5 hr 5 hr 
G
ab
ap
en
tin
 N 30 30 30 30 30 30 30 30 30 30 
Mean 95.24 89.52 88.31 88.20 88.39 87.88 87.41 87.50 87.24 88.13 
SD 6.23 5.08 4.73 4.76 4.85 4.74 4.40 3.83 4.23 5.50 
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 N 30 30 30 30 30 30 30 30 30 30 
Mean 91.86 89.12 88.56 88.58 88.21 88.43 88.39 86.90 88.42 88.53 
SD 7.60 5.87 5.91 5.85 5.94 5.49 5.94 11.08 5.42 5.71 
P values 
Unpaired 
 t Test 
0.064 0.778 0.860 0.785 0.899 0.677 0.472 0.781 0.352 0.783 
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Mean 
Arterial 
Pressure - 
Postoperative 
5.5 hr 6 hr 8 hr 10 hr 12 hr 14 hr 16 hr 20 hr 24 hr 
G
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tin
 N 30 30 30 30 30 30 30 30 30 
Mean 89.23 89.40 88.74 87.91 87.66 87.93 87.80 87.18 86.73 
SD 6.78 6.94 5.31 4.98 4.87 6.20 6.43 5.33 4.90 
G
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 N 30 30 30 30 30 30 30 30 30 
Mean 88.88 88.07 90.29 89.03 88.79 88.81 88.23 88.37 88.28 
SD 6.06 6.15 7.83 5.79 5.78 5.03 6.24 6.17 6.02 
P values 
Unpaired t 
Test 
0.8312 0.4344 0.3754 0.4240 0.4152 0.5494 0.7920 0.4275 0.2806 
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Majority of the Gabapentin group patients belonged had a mean 
postoperative MAP of 88.44 mm Hg with a mean range of 87-95 mm hg. In the 
Granisetron group patients had a mean MAP of 88.72 mm Hg with a mean 
range of 87-92 mm Hg. The association between the intervention groups and 
postoperative mean arterial pressure is considered to be not statistically 
significant since p > 0.05 as per unpaired t test 
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SPO2  
 
 
SPO2 
Postoperative 0 hr 1 hr 1.5 hr 2 hr 2.5 hr 3 hr 3.5 hr 4 hr 4.5 hr 5 hr 
G
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tin
 N 30 30 30 30 30 30 30 30 30 30 
Mean 98.97 99.00 98.90 98.97 98.87 98.83 98.97 99.00 99.00 98.97 
SD 0.18 0.00 0.31 0.18 0.35 0.38 0.18 0.00 0.00 0.18 
G
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 N 30 30 30 30 30 30 30 30 30 30 
Mean 98.80 98.87 98.87 98.97 98.87 98.80 98.90 98.90 98.93 98.87 
SD 0.41 0.35 0.35 0.18 0.35 0.41 0.31 0.31 0.25 0.35 
P values 
Unpaired  
t Test 
0.347 0.443 0.694 1.000 1.000 0.744 0.30 0.083 0.161 0.169 
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SPO2 5.5 hr 6 hr 8 hr 10 hr 12 hr 14 hr 16 hr 20 hr 24 hr 
G
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en
tin
 N 30 30 30 30 30 30 30 30 30 
Mean 98.87 99.00 99.00 99.00 99.00 98.93 99.53 98.93 99.00 
SD 0.35 0.00 0.00 0.00 0.00 0.25 0.33 0.25 0.00 
G
ra
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 N 30 30 30 30 30 30 30 30 30 
Mean 98.87 98.93 98.93 99.00 99.00 98.83 98.53 98.77 99.00 
SD 0.35 0.25 0.25 0.00 0.00 0.38 0.33 0.43 0.00 
P values 
Unpaired t Test 1.0000 0.1608 0.1608 1.0000 1.0000 0.2354 1.0000 0.0739 1.0000 
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Majority of the Gabapentin group patients belonged had a mean 
postoperative SPO2 of 98% with a mean range of 98-99 %. In the Granisetron 
group patients had a mean SPO2 of 99% with a mean range of 99-100 %. The 
association between the intervention groups and postoperative peripheral 
capillary oxygen saturation is considered to be not statistically significant since 
p > 0.05 as per unpaired t test 
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Visual Analogue Scale 
 
 
Visual 
Analogue 
Score - 
Postoperative 
0 hr 1 hr 1.5 hr 2 hr 2.5 hr 3 hr 3.5 hr 4 hr 4.5 hr 5 hr 
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 N 30 30 30 30 30 30 30 30 30 30 
Mean 0.03 0.10 0.17 0.40 0.70 0.93 1.37 1.57 1.87 2.23 
SD 0.18 0.31 0.38 0.50 0.60 0.64 0.61 0.73 0.86 1.01 
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 N 30 30 30 30 30 30 30 30 30 30 
Mean 0.00 0.00 0.00 0.03 0.03 0.13 1.13 1.23 1.40 2.13 
SD 0.00 0.00 0.00 0.18 0.18 0.35 0.35 0.50 0.62 0.63 
P values 
Unpaired t Test 
0.325
6 
0.083
1 
0.022
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Visual Analogue 
Score - 
Postoperative 
5.5 hr 6 hr 8 hr 10 hr 12 hr 14 hr 16 hr 20 hr 24 hr 
G
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 N 30 30 30 30 30 30 30 30 30 
Mean 2.60 2.40 2.23 2.33 2.63 2.63 2.63 2.63 2.73 
SD 1.16 1.30 1.28 1.35 1.54 1.65 1.67 1.63 1.57 
G
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N 30 30 30 30 30 30 30 30 30 
Mean 2.30 2.23 2.03 2.23 2.50 2.33 2.43 2.43 2.47 
SD 0.72 0.75 0.97 1.10 0.65 0.66 0.68 0.83 0.85 
P values Unpaired t 
Test 0.07 0.08 0.07 0.08 0.07 0.08 0.08 0.099 0.0834 
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Results  
By conventional criteria the association between the intervention groups 
and visual analogue score postoperatively is considered to be statistically 
insignificant since p > 0.05 as per unpaired t test.  
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DISCUSSION 
The optimal anti – emetic regimen for post-operative nausea and 
vomiting (PONV) is one which would decrease the incidence of nausea and 
vomiting without increasing the risk of unacceptable side effects like sedation , 
extrapyramidal symptoms , dry mouth , hypotension etc. Inspite of much 
attention paid to Post Operative Nausea and Vomiting the optimal anti-emetic 
regimen in surgical setting has still has not been established. 
Gabapentin is an anti-convulsant drug used to treat partial seizure and 
neuropathic pain. Recently , it has been found that , it has an anti-emetic 
properties.  
The observation and results revealed that there is no significant 
difference between Graniseton group and Gabapentin group in preventing post 
operative nausea and vomiting. This is manifested as similar Visual Analogue 
Scale (VAS) and intraoperative and post operativehaemodynamics. These 
findings are similar to results previously published studies and meta analysis of 
randomized controlled studies comparing these two drugs.  
DEMOGRAPHIC PROFILE : 
This present study included the patient posted for middle ear surgery. 
The demographic profile of our patients was comparable in both the groups 
with the respect to age, BMI, ASA Physical status. There is no difference in the 
duration of surgery among the two groups. 
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INTRAOPERATIVE PERIOD  
HAEMODYNAMICS 
A study done by Morteza Heidari, Azim Honarmand et al compared 
Granisetron and Gabapentin in preventing post operative nausea and vomiting 
after middle ear surgery in adults. Both group of patient intraoperative vitals 
were recorded. There is no significant difference in intra operative vitals 
between the two groups. 
The present study also revealed that there is no significant difference in 
intra operative vitals between the Granisetron and Gabapentin groups.  
POST OPERATIVE PERIOD  
Visual Analogue Scale 
A study done by MortezaHeidari, Azim Honarm and et al compared 
Granisetron and Gabapentin group. The severity of nausea was assessed by 
using Visual Analogue Score. Results showed that there is no significant 
difference between the two groups with respect to Visual Analogue Scale 
(VAS). 
The present study also assessed the Visual Analogue Scale (VAS) post 
operatively for 24 hrs. It revealed that there is no significant difference in 
Visual Analogue Scale (VAS) for vomiting between the Granisetron and 
Gabapentin group. This result is similar to the study done previously. 
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HEART RATE  
A study done by Morteza Heidari, Azim Honarm and et al compared 
Granisetron and Gabapentin group with respect to post-operative heart rate . 
The result showed that there is no significant difference in post-operative heart 
rate between the two groups. 
The present study also assessed the post-operative heart rate for 24 hrs. 
it revealed that there is no significant difference in HR post operatively 
between the Granisetron and Gabapentin group. This result correlates with the 
study done previously. 
SYSTOLIC BLOOD PRESSURE  
A study done by Morteza Heidari, Azim Honarm and et al compared 
Granisetron and Gabapentin group with respect to post-operative systolic blood 
pressure. The result showed that there is no significant difference in post-
operative systolic blood pressure between the two groups. 
The present study also assessed the post-operative Systolic Blood 
Pressure (SBP) for 24 hrs. it revealed that there is no significant difference in 
Systolic Blood Pressure (SBP) post operatively between the Granisetron and 
Gabapentin group. This result correlates with the study done previously. 
DIASTOLIC BLOOD PRESSURE  
A study done by MortezaHeidari,AzimHonarmand et al compared 
Granisetron and Gabapentin group with respect to post-operative diastolic 
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blood pressure . The result showed that there is no significant difference in 
post-operative diastolic blood pressure between the two groups. 
The present study also assessed the post operative Diastolic Blood 
Pressure (DBP) for 24 hrs. it revealed that there is no significant difference in 
Diastolic Blood Pressure (DBP) post operatively between the Granisetron and 
Gabapentin group. This result correlates with the study done previously. 
MEAN ARTERIAL PRESSURE 
A study done by Morteza Heidari,Azim Honarm and et al compared 
Granisetron and gabapentin group with respect to post-operative mean arterial 
pressure. The result showed that there is no significant difference in post-
operative mean arterial pressure between the two groups. 
The present study also assessed the post-operative Mean Arterial 
Pressure (MAP) for 24 hrs. It revealed that there is no significant difference in 
Mean Arterial Pressure (MAP) post operatively between the Granisetron and 
Gabapentin group. This result correlates with the study done previously. 
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SUMMARY 
To summarize, on conducting a double blinded randomized control 
study on patients undergoing middle ear surgery, it has been concluded that 
Granisetron and Gabapentin groups have equal anti- emetic effect. Intra 
operative and Post operative haemodynamics were also noted among the two 
groups and found to be insignificant. No incidence of side effects like 
respiratory depression, drowsiness, vertigo and headache noted among the both 
the group .  
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CONCLUSION 
In this study we can safely conclude that Gabepentin group and 
Granisetron group have equal anti-emetic effects without any significant side 
effects and it is useful in preventing post-operative nausea and vomiting in 
middle ear surgeries. 
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INFORMATION TO THE PARTICIPANTS 
Investigator: Dr.V.Balakrishnan 
Name of the Participant: 
Title: “A prospective, randomized study comparing the antiemetic effect of 
intravenous Granisetron and oral Gabapentin in preventing postoperative 
nausea and vomiting after middle ear surgery in adults” 
You are invited to take part in this research study. We have got approval 
from the IEC. You are asked to participate because you satisfy the eligibility 
criteria. We want to compare and study the safety and antiemetic effect of 
Gabapentin and Granisetron in preventing postoperative nausea and vomiting 
in patients undergoing middle ear surgeries. 
What is the Purpose of the Study: 
For Middle ear sureries Granisetron and Gabapentin were used as a 
premedication in prevention of postoperative nausea and vomiting  in adults. 
Severity of PONV assesed by using Visual Analogue Scale (VAS). 
The Study Design: 
All the patients in the study will be divided into two groups. 
Group 1 – patients receiving intravenous Granisetron 3mg 2 mins before 
induction 
Group 2 – patients receiving Gabapentin 300mg orally 1hr before induction 
All patients will be given general anaesthesia 
  
BENEFITS 
Middle ear surgeries are more prone for Nausea & Vomiting in the 
postoperative period, the use of Gabapentin & Granisetron are effective in 
preventing PONV. 
DISCOMFORTS AND RISK: 
The study poses hardly any risk as the drugs have been in use for a long 
time in preventing post operative nausea and vomiting and any side effects 
produced by these drugs will be appropriately dealt with. Patients who don’t 
want to be part of study may withdraw as per their wish. 
  
  
PATIENT CONSENT FORM 
TITLE: 
Comparison of Granisetron vs Gabapentin in preventing postoperative 
nausea and vomiting after middle ear surgery in adults”. 
Study Centre: Institute of Anaesthesiology and Critical Care, Rajiv 
Gandhi Govt. General Hospital, Madras Medical 
College, Chennai 600003. 
Participant Name:    Age:  Sex:  I.P. No: 
I confirm that I have understood the purpose of procedure for the above 
study. I have had the opportunity to ask questions and all my questions and 
doubts have been answered to my satisfaction. 
I understand that my participation in the study is voluntary and that I am 
free to withdraw at anytime without giving any reason. 
I understand that the investigator, regulatory authorities and the ethics 
committee will not need my permission to look at my health records both in 
respect to current study and any further research that may be conducted in 
relation to it, even if I withdraw from the study. I understand that my identity 
will not be revealed in any information released to third parties or published, 
unless as required under the law. I agree not to restrict the use of any data or 
results that arise from the study. 
Time:  
Date:  
Place:  
Signature of the investigator:  Signature/thumb impression of patient 
 
Name of the investigator:   Patient name  
  
 
 
  
  
 
 
  
 
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
 
